David Calimag, DO
Family Medicine · New Lenox, ILNPI 1922112184
Payments from drug & device makers
Across 92 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$376
- AstraZeneca$200
- Pfizer$169
- AbbVie$154
- Lilly USA, LLC$125
- Phathom Pharmaceuticals, Inc.$120
- plus $889 from 21 others
What the payments were for
- Food & beverage$2,033100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $376 |
| AstraZeneca | 11 | $200 |
| Pfizer | 8 | $169 |
| AbbVie | 8 | $154 |
| Lilly USA, LLC | 6 | $125 |
| Phathom Pharmaceuticals, Inc. | 3 | $120 |
| Banner Life Sciences, LLC | 5 | $116 |
| Dexcom, Inc. | 3 | $109 |
| Boehringer Ingelheim | 3 | $82 |
| Exact Sciences | 4 | $73 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| E.r. Squibb & Sons, L.L.C. | 2 | $52 |
| Bayer | 3 | $45 |
| Astellas Pharma US Inc | 2 | $44 |
| Johnson & Johnson | 2 | $42 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Corcept Therapeutics | 1 | $28 |
| Medtronic | 1 | $25 |
| Abbott | 1 | $23 |
| Novartis | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$2,033 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 168 | $188,300 |
| JardianceEmpagliflozin | 74 | $111,210 |
| FarxigaDapagliflozin Propanediol | 64 | $79,468 |
| MounjaroTirzepatide | 53 | $73,993 |
| JanuviaSitagliptin Phosphate | 14 | $22,543 |
| EliquisApixaban | 17 | $19,819 |
| InvokanaCanagliflozin | 12 | $14,086 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $8,761 |
| ZoloftSertraline Hcl | 13 | $8,068 |
| Spiriva RespimatTiotropium Bromide | 13 | $7,661 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,932 |
| Rosuvastatin Calcium | 314 | $4,999 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $4,844 |
| Potassium Chloride | 126 | $3,710 |
| Fentanyl | 13 | $3,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $376 | $188,300168 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $82 | $118,87087 claims |
| AstraZenecaFarxiga, Symbicort | $200 | $85,40183 claims |
| Lilly USA, LLCMounjaro | $125 | $73,99353 claims |
| PfizerEliquis | $169 | $19,81917 claims |
| Johnson & JohnsonInvokana | $42 | $14,08612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in New Lenox
- Mark ChristensenNew Lenox$2.1M
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.